SPOTLIGHT -
Updates on treatment of wet AMD and DME with brolucizumab
Jill Hopkins, MD, discusses results from phase 3a of the Merlin trial for brolucizumab as a treatment for wet AMD and provides updates on KESTREL and KITE trials for the treatment of diabetic macular edema.
Read More
Dissecting ARMOR study data on antibiotic resistance in ophthalmology
At the 2021 American Academy of Ophthalmology annual meeting, Penny Asbell, MD, FACS, MBA, discussed data from the ARMOR study and its effects on treating ophthalmic infections, such as endophthalmitis.
Cell therapy emerges as treatment option for corneal endothelial disease
New cell therapy drug makes treatment of corneal endothelial disease more accessible.
New sustained-release anti-VEGF formulation EYP-1901 proves safe, effective in phase 1 trials
Jay Duker, MD, discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.
Promising results from phase 2b study of AR-15512 for the treatment of dry eye
At AAO 2021, Aerie Pharmaceuticals presented the results of their phase 2b clinical trial of AR-15512, a triple 8 antagonist, for the treatment of dry eye.
Heru addresses gaps in vision care with wearable diagnostic platform
Mohamed Abou Shousha, MD, PhD, discusses Heru’s wearable AI-powered diagnostic devices at AAO 2021.
Verana Health unveils new quality measures dashboard at AAO 2021
Verana Health showcases the VeraQ quality measures dashboard for the IRIS registry report at AAO 2021.
AAO recap: Scientific findings and interviews from New Orleans
A brief overview of the plethora of findings presented at the 2021 American Academy of Ophthalmology meeting held November 12-15 in New Orleans, LA.
FDA-approved eye drops target presbyopia patients
Cathleen McCabe, MD, discusses VUITY, the first and only FDA-approved eye drop to treat age-related blurry near vision, and how it provides opportunities for patients looking for spectacle independence.
DME: Changes to CST linked to worse visual outcomes
Ajay Kuriyan, MD, discusses fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular edema in clinical trial setting.